Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 2021
Historique:
received: 17 02 2020
revised: 11 10 2020
accepted: 12 10 2020
pubmed: 24 10 2020
medline: 24 4 2021
entrez: 23 10 2020
Statut: ppublish

Résumé

Radiation pneumonitis (RP) can be a potential fatal toxicity of stereotactic body radiation therapy (SBRT) for medically inoperable non-small cell lung cancer (NSCLC). This study aimed to examine the risk factors that predict RP and explore dosimetric tolerance for safe practice in a large institutional series of NSCLC patients. Patients with early-stage and locally recurrent NSCLC who received lung SBRT between 2002 and 2015 formed the study population. The primary endpoint was grade 2 or above radiation pneumonitis (RP2). Lungs were re-contoured consistently by one radiation oncologist according to the RTOG atlas for organs at risk. Dosimetric factors were computed consistently with exclusion of gross tumor volume of either ipsilateral, contralateral, or total lungs. A total of 339 patients were eligible. With a median follow-up of 47 months, RP2 was recorded in 10% patients. History of respiratory comorbidity, previous thoracic radiation, right lung location, mean lung doses of total or ipsilateral lung, and total lung volume receiving 20 Gy were all significantly associated with the risk of RP2. The dosimetric parameters of contralateral lung, including mean dose and volume receiving more than 5, 10, and 20 Gy, were not significantly associated with RP2 (ps > 0.05). A model of combining significant clinical and dosimetric factors had a predictive accuracy AUC of 0.76. According to this model, RP2 can be limited to <10% should the patient have no previous lung radiation and the mean dose of total and ipsilateral lungs be kept less than 6 Gy and 20 Gy, respectively. Dosimetric factors of total or ipsilateral lung together with important clinical factors were significant risk factors for symptomatic radiation pneumonitis after SBRT. Constraining mean lung dose can limit clinically significant lung toxicity.

Sections du résumé

BACKGROUND AND PURPOSE
Radiation pneumonitis (RP) can be a potential fatal toxicity of stereotactic body radiation therapy (SBRT) for medically inoperable non-small cell lung cancer (NSCLC). This study aimed to examine the risk factors that predict RP and explore dosimetric tolerance for safe practice in a large institutional series of NSCLC patients.
MATERIALS AND METHODS
Patients with early-stage and locally recurrent NSCLC who received lung SBRT between 2002 and 2015 formed the study population. The primary endpoint was grade 2 or above radiation pneumonitis (RP2). Lungs were re-contoured consistently by one radiation oncologist according to the RTOG atlas for organs at risk. Dosimetric factors were computed consistently with exclusion of gross tumor volume of either ipsilateral, contralateral, or total lungs.
RESULTS
A total of 339 patients were eligible. With a median follow-up of 47 months, RP2 was recorded in 10% patients. History of respiratory comorbidity, previous thoracic radiation, right lung location, mean lung doses of total or ipsilateral lung, and total lung volume receiving 20 Gy were all significantly associated with the risk of RP2. The dosimetric parameters of contralateral lung, including mean dose and volume receiving more than 5, 10, and 20 Gy, were not significantly associated with RP2 (ps > 0.05). A model of combining significant clinical and dosimetric factors had a predictive accuracy AUC of 0.76. According to this model, RP2 can be limited to <10% should the patient have no previous lung radiation and the mean dose of total and ipsilateral lungs be kept less than 6 Gy and 20 Gy, respectively.
CONCLUSION
Dosimetric factors of total or ipsilateral lung together with important clinical factors were significant risk factors for symptomatic radiation pneumonitis after SBRT. Constraining mean lung dose can limit clinically significant lung toxicity.

Identifiants

pubmed: 33096168
pii: S0167-8140(20)30851-3
doi: 10.1016/j.radonc.2020.10.015
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-238

Subventions

Organisme : NCI NIH HHS
ID : R01 CA142840
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Yongmei Liu (Y)

Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Weili Wang (W)

Department of Radiation Oncology, University Hospitals/Seidman Cancer Center and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA.

Kevin Shiue (K)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Huan Yao (H)

Department of Radiation Oncology, University Hospitals/Seidman Cancer Center and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA.

Alberto Cerra-Franco (A)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Ronald H Shapiro (RH)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA; Department of Radiation Oncology, Richard L. Roudebush VAMC, Indianapolis, USA.

Ke Colin Huang (KC)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Douglas Vile (D)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Mark Langer (M)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Gordon Watson (G)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Greg Bartlett (G)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Huisi Ai (H)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Francis Sheski (F)

Department of Pulmonary Medicine, Indiana University School of Medicine, Indianapolis, USA.

Jian-Yue Jin (JY)

Department of Radiation Oncology, University Hospitals/Seidman Cancer Center and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA.

Rich Zellars (R)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Pingfu Fu (P)

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, USA.

Tim Lautenschlaeger (T)

Department of Radiation Oncology, Indiana University School of Medicine and Indiana University Health, Indianapolis, USA.

Feng-Ming Spring Kong (FS)

Department of Radiation Oncology, University Hospitals/Seidman Cancer Center and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA; Department of Clinical Oncology, Hong Kong University Shenzhen Hospital, and Hong Kong University, Hong Kong, China. Electronic address: kong0001@hku.hk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH